Management raised EPS guidance while targeting second-half growth acceleration led by cardiac ablation and new product launches.
| Quarter | Q1 FY26 |
|---|---|
| Call date | 2025-08-19 |
| Length | 71 minutes |
| EPS | $1.26 |
| EPS consensus | $1.23 |
| Revenue | $8.6B |
What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.
Other quarters: Q1 FY27 · Q4 FY26
Read the full Q1 FY26 earnings call transcript
All MDT earnings · Back to MDT overview
Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.